- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02924389
Dolutegravir in Reservoirs
Defining Antiretroviral Pharmacology Within HIV-1 Reservoirs of Males and Females
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Emerging evidence indicates that sites outside of blood plasma, such as peripheral blood mononuclear cells (PBMCs) and gut-associated lymphoid tissue, remain reservoirs for HIV and play critical roles in viral persistence despite long-term potent combination antiretroviral therapy (cART). Suboptimal ARV drug concentrations within these reservoirs are thought to contribute to our inability to fully eradicate HIV. In addition, host factors such as sex have been found to impact ARV drug exposure within these sites and effect key outcomes such as time to virologic suppression. The understanding of reservoir site pharmacology and the impact on sex is limited due to several barriers: 1) Difficulty in sampling reservoir sites intensively and 2) Scarcity of women enrolled in HIV clinical research studies. Optimal drug concentrations are ideally determined early in drug development by dose-ranging studies that require intensive blood plasma sampling; this methodology is impractical to employ within tissue sites. To mitigate these barriers, the researchers propose to study the pharmacology of the integrase strand transfer inhibitor dolutegravir (DTG) within three body compartments: blood plasma, PBMCs, and rectal tissue using a novel integrated population pharmacokinetic-viral dynamic (PK-VD) modeling approach. This PK-VD modeling strategy generates concentration-response relationships with limited sampling and dosing simulations ideally suited to reservoir sites.
The primary aim of this study is to validate the integrated population PK-VD model that quantitatively describes the relationship between dolutegravir (DTG) exposure and HIV viral decay in blood plasma. The second aim of this study is to develop an integrated population pharmacokinetic-viral dynamic (PK-VD) model to describe the relationship between DTG exposure and HIV viral decay in peripheral blood mononuclear cells and rectal tissue reservoir sites. The third aim is exploratory and will investigate sex differences in DTG penetration into blood plasma, peripheral blood mononuclear cells and rectal tissue reservoirs reservoirs as well as its impact on the rectal microbiome.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
Atlanta, Georgia, United States, 30303
- Grady Health System
-
Atlanta, Georgia, United States, 30308
- Ponce De Leon Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- No ARVs in the last 6 months (from date of screening)
- No documented or suspected resistance to integrase inhibitors (dolutegravir, elvitegravir, raltegravir, or bictegravir).
- Creatinine Clearance >50 mL/min, as calculated by the Cockcroft-Gault equation within 90 days of screen
- Liver function testing, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase < 5 times upper limit of normal within 90 days of screen
- Intact gastrointestinal tract
- Able and willing to give informed consent
- Willing and eligible to initiate ARV therapy with Triumeq, DTG + Truvada (TDF/FTC), or DTG + Descovy (FTC/TAF)
Agree to receive from their provider and pay for a prescribed supply of the drug, Tivicay® (dolutegravir/DTG), with either Triumeq, or Truvada or Descovy as determined by their primary HIV provider
- Agree to take the prescribed medication by mouth
- Agree that they (the participant) is responsible for bringing these medications with them to their study visits
- Willing to undergo serial blood and rectal tissue sampling
- Female participants' must be willing to have a pregnancy test done at each visit. Female participants of childbearing potential (FCB) must agree to either commit to continued abstinence from heterosexual intercourse or to use a reliable form of birth control such as oral contraceptive pills, intrauterine device, Nexplanon, DepoProvera, permanent sterilization, or another acceptable method, as determined by the investigator for the duration of the study. FCB are defined as sexually mature women who have not undergone hysterectomy or bilateral oophorectomy or have not been naturally postmenopausal for at least 24 consecutive months (i.e have had menses at any time in preceding 24 months)
Exclusion Criteria:
- Pregnant or attempting to conceive now or during the course of the study
- Self-reported or documented current anal or rectal disease prohibiting safe anoscopy and biopsies, in investigator's opinion.
- Taking concurrent medications that interfere with DTG
- Bleeding diathesis
- Platelet count <50,000 mm3
- Medical condition that interferes with conduct of study, in investigator's opinion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Anti-retroviral (ARV) Naïve Males
Males diagnosed with HIV will undergo serial blood and tissue rectal sampling for twelve weeks after initiating ARV therapy as prescribed by their physician.
Participants will be treated with either Triumeq or Truvada with dolutegravir.
|
Tivicay is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
50 mg of Tivicay (dolutegravir) will be taken orally once a day.
Other Names:
Triumeq is a fixed-dose combination drug for the treatment of HIV/AIDS.
It is a combination of 600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine.
Triumeq will be taken orally once daily.
Truvada is a combination of emtriva and viread, both nucleoside analog HIV-1 reverse transcriptase inhibitors.
Truvada is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
One Truvada tablet (containing 200 mg/300 mg of emtricitabine and tenofovir disoproxil fumarate) will be taken orally once daily.
|
Other: Anti-retroviral (ARV) Naïve Females
Females diagnosed with HIV will undergo serial blood and tissue rectal sampling for twelve weeks after initiating ARV therapy as prescribed by their physician.
Participants will be treated with either Triumeq or Truvada with dolutegravir.
|
Tivicay is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
50 mg of Tivicay (dolutegravir) will be taken orally once a day.
Other Names:
Triumeq is a fixed-dose combination drug for the treatment of HIV/AIDS.
It is a combination of 600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine.
Triumeq will be taken orally once daily.
Truvada is a combination of emtriva and viread, both nucleoside analog HIV-1 reverse transcriptase inhibitors.
Truvada is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
One Truvada tablet (containing 200 mg/300 mg of emtricitabine and tenofovir disoproxil fumarate) will be taken orally once daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dolutegravir Concentration
Time Frame: Day 84 (hour 0 through 24)
|
Dolutegravir concentrations in blood plasma are assessed as the maximum dolutegravir concentration (Cmax) and 24 hour trough (lowest) concentration (C24h) of dolutegravir in micrograms per milliliter (µg/mL).
Blood samples for pharmacokinetics were obtained prior to dosing (hour 0) and 1, 2, 3, 4, 6, 8, and 24 hours after dosing.
|
Day 84 (hour 0 through 24)
|
Time of Maximum Dolutegravir Concentration
Time Frame: Day 84 (hour 0 through 24)
|
Time of maximum dolutegravir concentration is assessed in hours for the time periods of after the first dose and during steady state.
Blood samples for pharmacokinetics were obtained prior to dosing (hour 0) and 1, 2, 3, 4, 6, 8, and 24 hours after dosing.
|
Day 84 (hour 0 through 24)
|
Area Under the Dolutegravir Plasma Concentration vs Time Curve
Time Frame: Day 84 (hour 0 through 24)
|
The area under the dolutegravir plasma concentration vs time curve in a 24 hour period (AUC24h) is assessed in hours times micrograms per millimeters (h* µg/mL) for the time periods of after the first dose and during steady state.
Blood samples for pharmacokinetics were obtained prior to dosing (hour 0) and 1, 2, 3, 4, 6, 8, and 24 hours after dosing.
|
Day 84 (hour 0 through 24)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dolutegravir Exposure in Peripheral Blood Mononuclear Cells (PBMC)
Time Frame: Up to Day 84
|
Dolutegravir concentrations in peripheral blood mononuclear cells required for HIV viral load decline.
|
Up to Day 84
|
Dolutegravir Concentration in Rectal Tissue
Time Frame: Week 2, Week 6, Week 12
|
Rectal dolutegravir concentrations in rectal tissue stratified by virologic suppressors vs non-suppressors.
|
Week 2, Week 6, Week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Cecile Lahiri, MD, Emory University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- HIV Integrase Inhibitors
- Integrase Inhibitors
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Dolutegravir
- Triumeq
Other Study ID Numbers
- IRB00089025
- K23AI124913 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States
Clinical Trials on dolutegravir
-
ViiV HealthcareGlaxoSmithKlineCompletedHIV InfectionsUnited States
-
ViiV HealthcareCompleted
-
University of KwaZuluCentre for the AIDS Programme of Research in South AfricaRecruitingTuberculosis | HivSouth Africa
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompletedInfections, Human Immunodeficiency Virus and HerpesviridaeUnited States
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingHIVUnited States, Brazil, Puerto Rico, South Africa, Thailand
-
Fundación HuéspedViiV HealthcareCompletedHIV-1 InfectionArgentina
-
Thomas BenfieldRecruitingCardiovascular Diseases | HIV Infections | Hiv | Weight Change, Body | HIV Lipodystrophy | HIV CardiomyopathyDenmark
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States